Analysts Offer Insights on Healthcare Companies: Zafgen (NASDAQ: ZFGN) and Pharming Group (Other OTC: PHGUF)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zafgen (ZFGNResearch Report) and Pharming Group (PHGUFResearch Report).

Zafgen (ZFGN)

Cowen & Co. analyst Yaron Werber maintained a Hold rating on Zafgen today. The company’s shares opened today at $1.35, close to its 52-week low of $1.25.

According to TipRanks.com, Werber is a 4-star analyst with an average return of 12.5% and a 61.2% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

Zafgen has an analyst consensus of Strong Buy, with a price target consensus of $6.75.

See today’s analyst top recommended stocks >>

Pharming Group (PHGUF)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with a price target of $2.50. The company’s shares opened today at $0.85, close to its 52-week low of $0.74.

Pantginis wrote:

“Valuation and potential impediments to achieving it. We reiterate our Buy rating and €2.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include, lack of meaningful market penetration, failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”

According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.8% and a 33.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $2.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.